newsfilter
← Latest News
GlobeNewswire·

Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts

Operating capital runway sufficient into the fourth quarter of 2026 In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8 data submitted in late 2025Anticipated